Acute Necrotizing Encephalopathy

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 21 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

On this page19 sections

Article Summary

Acute Necrotizing Encephalopathy—often shortened to ANE—is a rare but very serious brain illness that usually starts suddenly during or just after a feverish infection (most often a virus like influenza). In ANE, the body’s immune system reacts in an extreme way and creates a “cytokine storm.” This storm damages small blood vessels and brain cells, especially deep in the brain (the thalami), and sometimes in...

Key Takeaways

  • This article explains Other names in simple medical language.
  • This article explains Types in simple medical language.
  • This article explains Causes in simple medical language.
  • This article explains Symptoms and signs in simple medical language.
Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Definition

Necrotizing Encephalopathy—often shortened to ANE—is a rare but very serious brain illness that usually starts suddenly during or just after a feverish (most often a virus like influenza). In ANE, the body’s immune system reacts in an extreme way and creates a “cytokine storm.” This storm damages small blood vessels and brain cells, especially deep in the brain (the thalami), and sometimes in the , , and white matter. People—most commonly young children, but also adults—can become very sick within hours to days, with , sleepiness, seizures, and sometimes coma. ANE is not the same as an infection of the brain () where germs directly invade the brain; in ANE, the injury is mostly the body’s inflammatory reaction to an infection. Characteristic brain scans () show symmetrical lesions in both thalami, often with , necrosis (cell death), and sometimes small bleeds. PMC+2brainanddevelopment.com+2

Acute necrotizing encephalopathy (ANE) is a rare, fast-moving brain disease that usually happens a few days after a illness (like influenza). The immune system overreacts (“cytokine storm”), the blood-brain barrier becomes leaky, and toxic injures deep gray-matter areas (classically both thalami), brainstem, cerebellum, and white matter. MRI typically shows symmetrical thalamic lesions. ANE can strike babies, children, and adults; outcomes range from full recovery to or death. A form, ANE1, is caused by pathogenic variants in RANBP2 and can recur in families with incomplete penetrance. Early recognition and prompt (especially early high-dose steroids) plus supportive neurocritical care improve outcomes. There is no universally accepted, high-quality, randomized treatment guideline yet; evidence comes from observational studies and case series. PubMed+3PMC+3PMC+3

A preceding infection (often influenza; also SARS-CoV-2, dengue and others) triggers a runaway immune reaction. High levels of IL-6 and other cytokines damage brain microvessels, cause , and necrosis without direct viral invasion of neurons in many cases. In ANE1, RANBP2 dysfunction likely disrupts nucleocytoplasmic transport, mitochondrial placement, and immune responses—making the brain more vulnerable to -related cytokine surges. The hallmark radiology pattern is , symmetric, often hemorrhagic thalamic injury, with possible brainstem and cerebellar involvement. PMC+2PMC+2

Other names

  • Acute Necrotizing Encephalopathy of Childhood (ANEC) – a historic name because many cases are in children. Adults can be affected too. brainanddevelopment.com

  • Familial acute necrotizing encephalopathy / ANE1 – a genetic form linked to variants in the RANBP2 gene; episodes are often triggered by fevers and can recur. ScienceDirect+2Frontiers+2

  • Sporadic ANE – cases with no known RANBP2 mutation. PMC

  • Infection-associated ANE – ANE following viral infections such as influenza or COVID-19. PMC+2PMC+2

Types

  1. Sporadic ANE – single episode after an infection; no known ANE gene variant. PMC

  2. Familial/genetic ANE (ANE1, RANBP2-related) – tendency; attacks often start with fever and may recur. ScienceDirect+1

  3. ANE – more than one attack in the same person (common in ANE1). PMC

  4. Adult- ANE – similar process seen in adults, sometimes after COVID-19 or influenza. PMC+1

  5. Hemorrhagic ANE – same pattern but with more bleeding inside the lesions on MRI. PMC

Causes

ANE is usually triggered by an infection; the brain injury is driven by the body’s immune response, not by the virus directly attacking the brain.

  1. Influenza A – the most frequently reported trigger worldwide. PMC+1

  2. Influenza B – also reported, with similar timing after fever. PMC

  3. SARS-CoV-2 (COVID-19) – adult and pediatric cases described; typical MRI and rapid course. PMC+1

  4. Human herpesvirus-6/7 – febrile infection can precede ANE. PMC

  5. Parainfluenza viruses – respiratory viruses occasionally linked to ANE. PMC

  6. Respiratory syncytial virus (RSV) – rare association in reports. PMC

  7. Enteroviruses – sometimes precede encephalopathy with ANE pattern. PMC

  8. Adenovirus – occasional trigger in case series. PMC

  9. Rotavirus/other GI viruses – less common but reported. PMC

  10. Mycoplasma pneumoniae – a respiratory infection that can set off post-infectious inflammation. PMC

  11. RANBP2 gene variant (ANE1) – that makes severe inflammatory brain injury more likely during fevers. ScienceDirect+1

  12. Younger age (children) – more cases in early childhood, though not exclusive. brainanddevelopment.com

  13. High fever/cytokine surge – the key mechanism is an excessive immune response with high IL-6 and other cytokines. Frontiers

  14. or multi-organ stress – associated with worse severity scores and outcomes. Frontiers

  15. Brainstem involvement on MRI – a type of linked to greater severity (part of the ANE Severity Score). Frontiers

  16. markers (e.g., high ) – reflect inflammation that often accompanies ANE. PMC

  17. Elevated enzymes during the illness – common lab abnormality with ANE flare. American Academy of Neurology

  18. Seasonal viral waves (e.g., influenza season) – more triggers circulating increases risk exposure. PMC

  19. Previous ANE episode – especially in ANE1, prior episodes indicate vulnerability to recurrence. PMC

  20. No identified trigger (rare) – sometimes, despite testing, no clear pathogen is found; the pattern still fits ANE. PMC

Symptoms and signs

  1. Fever that starts with a cold or flu-like illness, followed by brain symptoms. brainanddevelopment.com

  2. Sleepiness or reduced alertness (acute impaired consciousness). brainanddevelopment.com

  3. Seizures (convulsions) that may be focal or generalized. PMC

  4. Headache early in the course, often with vomiting. PMC

  5. Confusion or disorientation, sometimes rapid behavior change. PMC

  6. Irritability in infants/children; they may not interact normally. brainanddevelopment.com

  7. Weakness or low muscle tone (hypomyotonia). PMC

  8. Poor balance or ataxia if the cerebellum is involved. PMC

  9. Abnormal eye movements or facial weakness if the brainstem is affected. PMC

  10. Speech problems or not speaking at all (mutism) during the acute phase. PMC

  11. Coma in severe cases. brainanddevelopment.com

  12. Breathing problems requiring intensive care if brainstem control is impaired. PMC

  13. Liver enzyme elevation on blood tests during illness, sometimes with vomiting and dehydration. American Academy of Neurology

  14. Shock/low blood pressure in the most severe systemic inflammatory responses. Frontiers

  15. Persistent neurological difficulties after recovery (e.g., movement or learning problems), especially after severe episodes. PMC

Diagnostic tests

A) Physical examination (bedside assessment)

  1. General observation and vital signs – fever, heart rate, blood pressure, and oxygen levels show how sick the person is and guide urgent care. In ANE the jump from a simple viral illness to serious neurological decline can be very fast, so frequent re-checks are vital. brainanddevelopment.com

  2. Level of consciousness (e.g., Glasgow Coma Scale) – tracks alertness; dropping scores signal brain swelling or injury that needs emergency treatment. ANE often presents with acute impairment of consciousness. brainanddevelopment.com

  3. Full neurologic exam – checks pupils, eye movements, strength, tone, reflexes, sensation, and coordination. Findings may localize injury to deep gray matter or brainstem and help distinguish ANE from meningitis or stroke. BioMed Central

  4. Meningeal signs check (neck stiffness/photophobia) – usually absent in ANE (because it is not primary meningitis), which nudges doctors to look for non-infectious inflammatory brain injury. brainanddevelopment.com

  5. Signs of shock or organ stress – cold extremities, poor capillary refill, or low blood pressure suggest a severe inflammatory response and a higher ANE Severity Score risk pattern. Frontiers

B) “Manual” bedside neurologic tests

  1. Cranial nerve checks (face symmetry, gag, eye tracking) – help spot brainstem involvement (a poor prognostic marker in ANE). Frontiers

  2. Coordination tests (finger-to-nose/heel-to-shin) – may show ataxia when cerebellum or thalami are affected. PMC

  3. Motor tone and reflex testing – hypotonia or abnormal reflexes can appear early and track disease progression. PMC

  4. Bedside language and cognition checks – brief tasks to assess speech, attention, and orientation; sudden decline supports an acute encephalopathy rather than a gradual condition. brainanddevelopment.com

  5. Seizure recognition and rapid response – staff watch for focal jerks, eye deviation, or unresponsiveness; early treatment reduces secondary brain injury. Seizures are common in ANE. PMC

C) Laboratory and pathological tests

  1. Complete blood count and inflammatory markers (CRP/ESR) – often elevated during the cytokine storm; help confirm a systemic inflammatory picture. PMC

  2. Liver panel (AST/ALT) – frequently elevated in ANE; supports the diagnosis when paired with typical MRI findings and normal ammonia. American Academy of Neurology

  3. Coagulation profile and D-dimer – may show activation of clotting pathways during severe inflammation; guides ICU care. PMC

  4. Cerebrospinal fluid (CSF) analysis – often shows high protein with normal white cells (albumin-cytologic dissociation), which supports ANE and helps rule out infectious encephalitis. PMC

  5. Viral testing (PCR/antigen) from respiratory samples – identifies the trigger (e.g., influenza, SARS-CoV-2), even if the CSF is negative. American Academy of Neurology+1

  6. Cytokine panel (e.g., IL-6), ferritin – can be markedly elevated and correlate with severity. Frontiers

  7. Genetic testing for RANBP2 – confirms ANE1 in families with recurrent episodes or suggestive imaging; useful for counseling and early recognition in future fevers. ScienceDirect+1

D) Electrodiagnostic tests

  1. Electroencephalogram (EEG) – commonly shows diffuse slowing, sometimes epileptiform activity or status epilepticus; supports the diagnosis of acute encephalopathy and guides seizure treatment. PMC

E) Imaging tests (cornerstone of diagnosis)

  1. Brain MRI with diffusion, FLAIR, and susceptibility (SWI/GRE) – the key test. Typical findings are bilateral, symmetrical thalamic lesions that may extend to the brainstem, cerebellum, and white matter; diffusion restriction reflects acute injury, and SWI may show micro-bleeds. These patterns strongly point to ANE. PMC

  2. Head CT (often first in emergencies) – can quickly show low-density lesions in both thalami, prompting urgent MRI and targeted care. CT is less sensitive than MRI but can be lifesaving when MRI is not immediately available.

Non-pharmacological treatments (therapies & others)

(Each is concise here; all are standard critical-care measures adapted to ANE. Evidence quality varies; many are extrapolated from pediatric neurocritical care and encephalopathy management.)

  1. Rapid escalation to PICU/ICU care – Early transfer enables airway, breathing, circulation (ABC) stabilization; seizure control; and timely immunotherapy within the first 24 hours, which is associated with better outcomes. PMC+1

  2. Airway protection & mechanical ventilation – Indicated for depressed consciousness, refractory seizures, or respiratory failure; ensures oxygenation and controlled CO₂ to limit intracranial pressure (ICP) spikes. PMC

  3. Early, aggressive seizure management (non-drug framework: protocols, EEG monitoring) – Continuous EEG, seizure protocols, and neuroprotective sedation complement antiseizure drugs to prevent secondary brain injury. Neurocritical Care Society

  4. ICP-lowering bundle (positioning, head-of-bed 30°, neutral neck, minimize agitation) – First-line non-invasive steps lower venous congestion and ICP while other therapies are being started. PMC

  5. Hyperosmolar therapy framework – Protocolized use of hypertonic saline or mannitol to treat suspected intracranial hypertension (the drugs themselves appear in the “Drugs” section). Non-pharm element is protocolization and monitoring. PMC

  6. External Ventricular Drain (EVD) when indicated – For hydrocephalus/very high ICP, an EVD allows CSF drainage and ICP monitoring; it’s lifesaving in selected pediatric neurocritical cases. PMC+1

  7. Targeted temperature management (avoid fever; consider normothermia) – Fever worsens cytokine injury; meticulous fever control is standard. Hypothermia is not routine but has been explored in pediatric encephalopathy care. PMC

  8. Early rehabilitation (PT/OT/speech) – Starts once the child/adult is medically stable; supports motor, cognitive, and communication recovery after ANE. Boston Children’s Hospital

  9. Nutrition optimization – Early enteral feeding with adequate protein and micronutrients supports brain recovery; dietitians adjust to metabolic needs and swallowing risk. PMC

  10. Dysphagia screening & aspiration prevention – Post-ANE patients often have impaired swallow; speech therapists and modified diets prevent pneumonia and malnutrition. Boston Children’s Hospital

  11. Neuro-psychological support & cognitive rehab – Structured cognitive retraining addresses attention, memory, and executive deficits common after ANE. Boston Children’s Hospital

  12. Family education & genetic counseling (ANE1) – Families with RANBP2 variants should receive counseling about recurrence risk, fever protocols, and early access to care. MedlinePlus

  13. Infection control practices – Isolation when appropriate, hand hygiene, and vaccination counseling reduce future viral triggers. CDC

  14. Return-to-school planning – Individualized educational plans and accommodations improve long-term outcomes. Boston Children’s Hospital

  15. Pressure-injury, DVT, and stress-ulcer prevention bundles – Standard ICU harm-reduction measures mitigate complications during prolonged stays. PMC

  16. Therapeutic plasma exchange (PLEX) protocol (procedure) – Not a drug; as a procedure it can remove inflammatory mediators in severe cases when started early. ScienceDirect+1

  17. MRI-guided prognostication & monitoring – Serial MRI helps map lesion evolution and guide rehab intensity and counseling. PMC

  18. Tracheostomy & weaning pathway (when prolonged ventilation) – Facilitates long-term ventilation and rehab participation in severe cases. PMC

  19. Feeding tube (NG/PEG) when needed – Ensures safe nutrition and medication delivery in patients with prolonged dysphagia. Boston Children’s Hospital

  20. Decompressive craniectomy (last-resort) – Rarely considered for malignant cerebral edema/herniation when all else fails; evidence in encephalitis/ANE is limited and case-based. PubMed+1

Drug treatments

(Doses are typical examples for context—always follow local protocols and weight/renal adjustments. Evidence ranges from observational to case reports unless noted.)

  1. Methylprednisolone (IV pulse steroid) – Class: corticosteroid. Dose: often 20–30 mg/kg/day (max 1 g) IV for 3–5 days, then taper. Timing: start within 24 h of neuro-worsening if ANE suspected. Purpose: blunt cytokine storm, stabilize BBB. Mechanism: down-regulates pro-inflammatory cytokines (e.g., IL-6), reduces edema. AEs: hyperglycemia, infection risk, hypertension, mood changes. Early use links to better outcomes. Frontiers+1

  2. Tocilizumab – Class: IL-6 receptor blocker. Dose: ~8–12 mg/kg IV once (weight-based), sometimes repeated. Timing: adjunct early if IL-6–driven storm suspected or steroid response inadequate. Purpose: dampen IL-6 signaling. AEs: infection risk, transaminitis. Growing case-level evidence in influenza/dengue/SARS-CoV-2-associated ANE. PMC+2Frontiers+2

  3. Intravenous immunoglobulin (IVIG) – Class: pooled immunomodulator. Dose: commonly 2 g/kg divided over 2–5 days. Timing: early adjunct; evidence mixed. Purpose: neutralize immune mediators. AEs: aseptic meningitis, thrombosis, hemolysis (rare). JKMS+1

  4. Anakinra – Class: IL-1 receptor antagonist. Dose: variable (e.g., 2–10 mg/kg/day SC/IV). Timing: refractory hyper-inflammation; extrapolated from cytokine storm/auto-inflammatory CNS disease. AEs: infection risk, neutropenia. Case-based rationale; ANE-specific evidence limited. PMC

  5. Oseltamivir – Class: neuraminidase inhibitor antiviral. Dose: weight-based; adults 75 mg bid; higher doses used in some severe influenza cases. Timing: asap in influenza-associated ANE. Purpose: reduce viral replication load. AEs: nausea, neuropsychiatric symptoms (rare). Case reports note benefit with steroids. PMC+1

  6. Peramivir (IV) – Class: neuraminidase inhibitor. Dose: single IV 600 mg (adult) or pediatric weight-based; repeat in severe cases per protocol. Timing: when oral/enteral oseltamivir not possible. AEs: diarrhea, neutropenia (rare). Extrapolated for severe influenza with encephalopathy. MN Department of Health

  7. Acyclovir (empiric) – Class: anti-HSV antiviral. Dose: 10 mg/kg IV every 8 h pending HSV PCR. Timing: start immediately while evaluating encephalitis to avoid missed HSV; stop if HSV ruled out. AEs: nephrotoxicity (hydrate). Standard encephalitis practice applied to ANE differentials. brainanddevelopment.com

  8. Levetiracetam – Class: antiseizure drug. Dose: load 20–60 mg/kg IV; maintenance 10–30 mg/kg bid. Timing: first-line status epilepticus control and prophylaxis. AEs: somnolence, irritability. Seizure control is crucial to prevent secondary injury. Neurocritical Care Society

  9. Fosphenytoin / Phenytoin – Class: antiseizure. Dose: load 15–20 mg PE/kg IV. Timing: second-line for status epilepticus. AEs: hypotension, arrhythmia (IV), rash. Neurocritical Care Society

  10. Midazolam (IV infusion for refractory seizures/sedation) – Class: benzodiazepine. Dose: bolus then infusion titrated. Purpose: seizure suppression and ICP control via sedation. AEs: hypotension, respiratory depression. Neurocritical Care Society

  11. Hypertonic saline (3% or higher)
    – Class: hyperosmolar agent. Dose: bolus 2–5 mL/kg or continuous infusion per ICP goals. Purpose: treat cerebral edema/ICP. AEs: hypernatremia, osmotic demyelination if over-rapid. Preferred over mannitol in many guidelines. PMC

  12. Mannitol – Class: osmotic diuretic. Dose: 0.25–1 g/kg IV bolus. Purpose: alternate ICP control. AEs: hypotension, renal stress, rebound ICP. PMC

  13. Antipyretics (Acetaminophen) – Class: analgesic/antipyretic. Dose: standard weight-based. Purpose: strict fever control to blunt inflammatory cascades and reduce metabolic demand. AEs: hepatotoxicity if overdosed. PMC

  14. Broad-spectrum antibiotics (empiric when sepsis suspected) – Class: antimicrobials (e.g., ceftriaxone + vancomycin per local policy). Purpose: cover bacterial causes while diagnostics pending; then de-escalate. AEs: C. difficile, allergies. brainanddevelopment.com

  15. Antiemetics & GI protection (ondansetron; PPIs if indicated) – Class: supportive. Purpose: reduce vomiting/aspiration risk and stress ulcers in the critically ill. AEs: QT prolongation (ondansetron), infection risk (PPIs). PMC

  16. Vasopressors (e.g., norepinephrine) – Class: adrenergic agonist. Purpose: maintain cerebral perfusion pressure during sedation/edema management. AEs: arrhythmias, ischemia. PMC

  17. Terlipressin/vasopressin adjuncts (select cases) – Class: vasopressors. Purpose: hemodynamic support; specialist use only. AEs: ischemia. (Supportive critical-care measure; not disease-specific.) PMC

  18. Rituximab (rare, rescue in refractory immune-mediated courses) – Class: anti-CD20 monoclonal antibody. Purpose: B-cell depletion when autoimmune overlap suspected; evidence mainly from autoimmune encephalitis, not ANE. AEs: infusion reactions, infections. ResearchGate

  19. Anesthetic coma agents (propofol/ketamine as per protocol) – Class: sedative-hypnotic/NDMA antagonist. Purpose: refractory status epilepticus and ICP control. AEs: hypotension; propofol infusion syndrome risk in children (caution). Neurocritical Care Society

  20. Antiviral tailored to non-influenza etiologies (e.g., ganciclovir for CMV if documented) – Class: DNA polymerase inhibitor. Purpose: pathogen-specific therapy when identified. AEs: marrow suppression. brainanddevelopment.com

Note: Items 14–20 are supportive or pathogen-directed therapies used based on differential diagnosis or complications; core disease-modifying evidence in ANE is strongest for early steroids, with mounting case-level support for tocilizumab; IVIG evidence is mixed. Frontiers+1

Dietary molecular supplements

  1. Thiamine (Vitamin B1) – Supports mitochondrial energy and reduces lactate; deficiency worsens encephalopathy. Often given empirically in critical illness. PMC

  2. Riboflavin (B2) – Cofactor in oxidative phosphorylation; sometimes included in “mitochondrial cocktails” for pediatric encephalopathies. ScienceDirect

  3. L-Carnitine – Shuttles fatty acids into mitochondria; pediatric studies suggest benefit in some acute encephalopathy syndromes. ScienceDirect

  4. Coenzyme Q10 – Electron transport chain cofactor; theoretical neuroprotective role in oxidative stress states. PMC

  5. Omega-3 fatty acids (EPA/DHA) – Anti-inflammatory membrane lipids; potential to modulate neuroinflammation (adjunctive only). PMC

  6. Vitamin D – Immunomodulatory; deficiency common, repletion reasonable in recovery. PMC

  7. Selenium – Antioxidant (glutathione peroxidase cofactor); maintain adequate intake in critical illness. PMC

  8. Zinc – Supports immune function and healing; avoid deficiency. PMC

  9. N-Acetylcysteine (NAC) – Glutathione precursor; antioxidant support in systemic inflammatory states (adjunct only). PMC

  10. Probiotics (GI axis) – In selected patients, may support gut barrier/immune modulation during recovery; choose evidence-based strains and avoid in severe immunosuppression. PMC

Important: No supplement has proven disease-modifying efficacy in ANE; use only as adjuncts under medical supervision. PMC

Immunity-booster / regenerative / stem-cell drugs

  1. Tocilizumab (IL-6R blocker) – Immune-modulating “booster” only in the sense of correcting hyper-inflammation; several case reports/series show promising outcomes as add-on to early steroids. No randomized trials yet. PMC+1

  2. Anakinra (IL-1RA) – Used in hyper-inflammatory CNS states; ANE-specific data sparse. Consider only in expert centers for refractory disease. PMC

  3. Rituximab – B-cell depletion for autoimmune encephalitis; not standard for ANE but sometimes considered in atypical/recurrent immune-mediated courses. ResearchGate

  4. Baricitinib/JAK inhibitors – Theoretical cytokine-pathway dampening in storms; no established role in ANE—use only in trials/specialist protocols. PMC

  5. IVIG (immunomodulator) – Can modulate immune networks; mixed evidence in ANE; may be used with steroids early. JKMS

  6. Stem-cell therapies – Not recommended for ANE outside research; no clinical evidence of benefit and potential risks. Focus should remain on early immunotherapy and neurocritical care. PMC

Surgeries/procedures

  1. External Ventricular Drain (EVD) – To drain CSF and directly monitor ICP in acute hydrocephalus/severe intracranial hypertension. Saves life by lowering pressure and allowing targeted therapy. PMC

  2. Decompressive craniectomy – Last-resort for malignant cerebral edema/herniation when maximal medical therapy fails. Evidence in encephalitis/ANE is limited to case reports; decisions are individualized. PubMed

  3. Tracheostomy – For prolonged ventilation/weaning and to enable rehab participation in severe neurologic injury. PMC

  4. Gastrostomy (PEG) – Long-term enteral nutrition and medication delivery in persistent dysphagia. Boston Children’s Hospital

  5. Therapeutic plasma exchange (PLEX) – Procedure that removes circulating inflammatory mediators; early use has been associated with favorable recovery in case reports/series. ScienceDirect

Preventions

  1. Annual influenza vaccination for patient and household. CDC

  2. Up-to-date routine vaccines (e.g., COVID-19, per national schedules). CDC

  3. Early medical review for fever with neurologic symptoms (confusion, severe headache, repeated vomiting, seizures). Boston Children’s Hospital

  4. Prompt antivirals for influenza in high-risk or severely ill patients as per guidelines. MN Department of Health

  5. Hand hygiene & infection-control habits at home and school. CDC

  6. Family genetic counseling if RANBP2 variant identified (ANE1). MedlinePlus

  7. Fever management plans (antipyretics, hydration, monitoring red flags). PMC

  8. Avoid delayed care during outbreaks—seek evaluation early rather than watch-and-wait when behavior or consciousness changes. CDC

  9. Rehab follow-up after recovery to reduce long-term complications. Boston Children’s Hospital

  10. Household vaccination literacy—know when to get treated and when to isolate. CDC

When to see doctors (red flags)

Seek emergency care immediately if, during or after a viral illness, you notice: sudden confusion, extreme sleepiness, repeated vomiting with headache, neck stiffness, new seizures, abnormal movements, vision changes, slurred speech, behavior change, or any loss of consciousness. Early MRI and early immunotherapy (especially high-dose steroids within ~24 h of neurologic decline) are time-sensitive. PMC+1

What to eat and what to avoid

Eat: balanced meals with adequate protein, fruits/vegetables (antioxidants), whole grains, sufficient fluids, and physician-guided micronutrient repletion (e.g., B-vitamins). Consider texture-modified diets if swallowing is affected; involve dietitians and speech therapists. Avoid: dehydration; alcohol/illicit drugs (older teens/adults); unnecessary herbal mixes that interact with antiseizure drugs; highly processed ultra-salted foods if sodium is being managed for ICP; and caffeine excess if it worsens sleep or anxiety. These are adjuncts and do not replace medical treatment. PMC+1

FAQs

  1. Is ANE infectious? – No; it’s usually an immune reaction after an infection, not the brain being directly infected (in many cases). PMC

  2. Can ANE happen more than once? – Yes, especially in ANE1 (RANBP2 variants) with incomplete penetrance; recurrences can follow new fevers. PMC+1

  3. What test confirms ANE? – Brain MRI showing bilateral thalamic lesions is classic; labs/CSF help exclude mimics. PMC

  4. Do steroids really help? – Early high-dose steroids (within ~24 h) are associated with better outcomes in pooled analyses/case series. Frontiers

  5. Is IVIG helpful? – Evidence is mixed; sometimes used with steroids. JKMS

  6. What about tocilizumab? – Increasing case-level evidence suggests benefit as add-on immunotherapy, especially when IL-6 is high. PMC+1

  7. Are antivirals used? – Yes, if a treatable virus (especially influenza) is suspected/confirmed, alongside immunotherapy. PMC

  8. Is surgery needed? – Rarely. EVD or decompressive craniectomy may be used in life-threatening ICP crises. PMC+1

  9. What is the outlook? – Outcomes vary widely; early diagnosis and treatment improve chances of recovery. PMC

  10. Can we prevent ANE? – You can lower risk by vaccination and very early care for severe febrile illnesses; genetic counseling for ANE1 families helps planning. CDC+1

  11. Does COVID-19 trigger ANE? – It has been reported; management principles are similar. Pedneur+1

  12. Is ANE the same as encephalitis? – No. ANE is often post-infectious immune injury with characteristic MRI, while encephalitis often implies direct infection of the brain. PMC

  13. What follow-up is needed? – Neurology, rehab, neuropsychology, and, where relevant, genetics. Boston Children’s Hospital

  14. Are there official guidelines? – No ANE-specific randomized guidelines; pediatric acute encephalopathy guidance supports early recognition and immunotherapy; neurocritical care guidelines guide ICP management. brainanddevelopment.com+1

  15. Can diet cure ANE? – No. Nutrition supports recovery but is never a replacement for urgent medical treatment. PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 17, 2025.

  1. Rare Diseases and Medical Genetics.[rxharun.com]
  2. i2023_IFPMA_Rare_Diseases_Brochure_28Feb2017_FINAL.[rxharun.com]
  3. the-UK-rare-diseases-framework.[rxharun.com]
  4. National-Recommendations-for-Rare-Disease-Health-Care-Summary.[rxharun.com]
  5. History of rare diseases and their genetic.[rxharun.com]
  6. health-care-and-rare-disorders.[rxharun.com]
  7. Rare Disease Registries.[rxharun.com]
  8. autoimmune-Rare-Genetic-Diseases.[rxharun.com]
  9. Rare Genetic Diseases.[rxharun.com]
  10. rare-disease-day.[rxharun.com]
  11. Rare_Disease_Drugs_e.[rxharun.com]
  12. fda-CDER-Rare-Diseases-Public-Workshop-Master.[rxharun.com]
  13. rare-and-inherited-disease-eligibility-criteria.[rxharun.com]
  14. FDA-rare-disease-list.pdf-rxharun.com1 Human-Gene-Therapy-for-Rare Diseases_Jan_2020fda.[rxharun.com]
  15. FDA-rare-disease-lists.[rxharun.com]
  16. 30212783fnl_Rare Disease.[rxharun.com]
  17. FDA-rare-disease-list.[rxharun.com]
  18. List of rare disease.[rxharun.com]
  19. Genome Res.-2025-Steyaert-755-68.[rxharun.com]
  20. uk-practice-guidelines-for-variant-classification-v4-01-2020.[rxharun.com]
  21. PIIS2949774424010355.[rxharun.com]
  22. hidden-costs-2016.[rxharun.com]
  23. B156_CONF2-en.[rxharun.com]
  24. IRDiRC_State-of-Play-2018_Final.[rxharun.com]
  25. IRDR_2022Vol11No3_pp96_160.[rxharun.com]
  26. from-orphan-to-opportunity-mastering-rare-disease-launch-excellence.[rxharun.com]
  27. Rare disease fda.[rxharun.com]
  28. England-Rare-Diseases-Action-Plan-2022.[rxharun.com]
  29. SCRDAC 2024 Report.[rxharun.com]
  30. CORD-Rare-Disease-Survey_Full-Report_Feb-2870-2.[rxharun.com]
  31. Stats-behind-the-stories-Genetic-Alliance-UK-2024.[rxharun.com]
  32. rare-and-inherited-disease-eligibility-criteria-v2.[rxharun.com]
  33. ENG_White paper_A4_Digital_FINAL.[rxharun.com]
  34. UK_Strategy_for_Rare_Diseases.[rxharun.com]
  35. MalaysiaRareDiseaseList.[rxharun.com]
  36. EURORDISCARE_FULLBOOKr.[rxharun.com]
  37. EMHJ_1999_5_6_1104_1113.[rxharun.com]
  38. national-genomic-test-directory-rare-and-inherited-disease-eligibilitycriteria-.[rxharun.com]
  39. be-counted-052722-WEB.[rxharun.com]
  40. RDI-Resource-Map-AMR_MARCH-2024.[rxharun.com]
  41. genomic-analysis-of-rare-disease-brochure.[rxharun.com]
  42. List-of-rare-diseases.[rxharun.com]
  43. RDI-Resource-Map-AFROEMRO_APRIL[rxharun.com]
  44. rdnumbers.[rxharun.com] .
  45. Rare disease atoz .[rxharun.com]
  46. EmanPublisher_12_5830biosciences-.[rxharun.com]

  1. https://www.ncbi.nlm.nih.gov/books/NBK208609/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC6279436/
  3. https://rarediseases.org/rare-diseases/
  4. https://rarediseases.info.nih.gov/diseases
  5. https://en.wikipedia.org/w/index.php?title=Category:Rare_diseases
  6. https://en.wikipedia.org/wiki/List_of_genetic_disorders
  7. https://en.wikipedia.org/wiki/Category:Genetic_diseases_and_disorders
  8. https://medlineplus.gov/genetics/condition/
  9. https://geneticalliance.org.uk/support-and-information/a-z-of-genetic-and-rare-conditions/
  10. https://www.fda.gov/patients/rare-diseases-fda
  11. https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/support-clinical-trials-advancing-rare-disease-therapeutics-start-pilot-program
  12. https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/jcph.2134
  13. https://www.mayoclinicproceedings.org/article/S0025-6196%2823%2900116-7/fulltext
  14. https://www.ncbi.nlm.nih.gov/mesh?
  15. https://www.rarediseasesinternational.org/working-with-the-who/
  16. https://ojrd.biomedcentral.com/articles/10.1186/s13023-024-03322-7
  17. https://www.rarediseasesnetwork.org/
  18. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/rare-disease
  19. https://www.raregenomics.org/rare-disease-list
  20. https://www.astrazeneca.com/our-therapy-areas/rare-disease.html
  21. https://bioresource.nihr.ac.uk/rare
  22. https://www.roche.com/solutions/focus-areas/neuroscience/rare-diseases
  23. https://geneticalliance.org.uk/support-and-information/a-z-of-genetic-and-rare-conditions/
  24. https://www.genomicsengland.co.uk/genomic-medicine/understanding-genomics/rare-disease-genomics
  25. https://www.oxfordhealth.nhs.uk/cit/resources/genetic-rare-disorders/
  26. https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-022-01026
  27. https://wikicure.fandom.com/wiki/Rare_Diseases
  28. https://www.wikidoc.org/index.php/List_of_genetic_disorders
  29. https://www.medschool.umaryland.edu/btbank/investigators/list-of-disorders/
  30. https://www.orpha.net/en/disease/list
  31. https://www.genetics.edu.au/SitePages/A-Z-genetic-conditions.aspx
  32. https://ojrd.biomedcentral.com/
  33. https://health.ec.europa.eu/rare-diseases-and-european-reference-networks/rare-diseases_en
  34. https://bioportal.bioontology.org/ontologies/ORDO
  35. https://www.orpha.net/en/disease/list
  36. https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions
  37. https://www.gao.gov/products/gao-25-106774
  38. https://www.gene.com/partners/what-we-are-looking-for/rare-diseases
  39. https://www.genome.gov/For-Patients-and-Families/Genetic-Disorders
  40. https://geneticalliance.org.uk/support-and-information/a-z-of-genetic-and-rare-conditions/
  41. https://my.clevelandclinic.org/health/diseases/21751-genetic-disorders
  42. https://globalgenes.org/rare-disease-facts/
  43. https://www.nidcd.nih.gov/directory/national-organization-rare-disorders-nord
  44. https://byjus.com/biology/genetic-disorders/
  45. https://www.cdc.gov/genomics-and-health/about/genetic-disorders.html
  46. https://www.genomicseducation.hee.nhs.uk/doc-type/genetic-conditions/
  47. https://www.thegenehome.com/basics-of-genetics/disease-examples
  48. https://www.oxfordhealth.nhs.uk/cit/resources/genetic-rare-disorders/
  49. https://www.pfizerclinicaltrials.com/our-research/rare-diseases
  50. https://clinicaltrials.gov/ct2/results?recrs
  51. https://apps.who.int/gb/ebwha/pdf_files/EB116/B116_3-en.pdf
  52. https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/sctm.21-0239
  53. https://www.nibib.nih.gov/
  54. https://www.nei.nih.gov/
  55. https://oxfordtreatment.com/
  56. https://www.nidcd.nih.gov/health/https://consumer.ftc.gov/articles/
  57. https://www.nccih.nih.gov/health
  58. https://catalog.ninds.nih.gov/
  59. https://www.aarda.org/diseaselist/
  60. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets
  61. https://www.nibib.nih.gov/
  62. https://www.nia.nih.gov/health/topics
  63. https://www.nichd.nih.gov/
  64. https://www.nimh.nih.gov/health/topics
  65. https://www.nichd.nih.gov/
  66. https://www.niehs.nih.gov/
  67. https://www.nimhd.nih.gov/
  68. https://www.nhlbi.nih.gov/health-topics
  69. https://obssr.od.nih.gov/.
  70. https://www.nichd.nih.gov/health/topics
  71. https://rarediseases.info.nih.gov/diseases
  72. https://beta.rarediseases.info.nih.gov/diseases
  73. https://orwh.od.nih.gov/

 

More from this topic
  1. Bilateral Perisylvian Polymicrogyria

    DefinitionBilateral perisylvian polymicrogyria is a brain development problem that starts before birth. In this condition, the brain area around the Sylvian fissures on both sides develops...

    March 10, 2026 • Rx Neurology (A - Z)
  2. Congenital Axonal Neuropathy with Encephalopathy

    DefinitionCongenital axonal neuropathy with encephalopathy is a very rare inherited nerve disease that starts at birth or very soon after birth. “Congenital” means present from birth....

    March 10, 2026 • Rx Neurology (A - Z)
  3. Congenital Absence of the Optic Chiasma

    DefinitionCongenital absence of the optic chiasma, also called congenital achiasma, is a very rare birth problem where the normal “crossing point” of the optic nerves (the...

    March 5, 2026 • Rx Neurology (A - Z)
  4. Congenital CN VI Palsy

    DefinitionCongenital CN VI palsy means a weak or paralyzed sixth cranial nerve (also called the abducens nerve) that is present from birth. This nerve controls the...

    March 4, 2026 • Rx Neurology (A - Z)
  5. Benign Congenital Sixth Cranial Nerve Palsy

    DefinitionBenign congenital sixth cranial nerve palsy is a problem with the sixth cranial nerve (also called the abducens nerve) that is present from birth and is...

    March 4, 2026 • Rx Neurology (A - Z)
  6. Congenital Abducens Nerve Palsy

    DefinitionCongenital abducens nerve palsy is a rare eye movement problem that is present from birth. In this condition, the sixth cranial nerve (also called the abducens...

    March 4, 2026 • Rx Neurology (A - Z)
  7. Tubulinopathies

    DefinitionTubulinopathies are a group of rare brain development disorders that happen when there is a harmful change (mutation) in one of the “tubulin” genes. Tubulin is...

    February 28, 2026 • Rx Neurology (A - Z)
  8. Complex Cortical Dysplasia with Other Brain Malformations 7 (CDCBM7)

    DefinitionComplex cortical dysplasia with other brain malformations 7 (CDCBM7) is a rare brain development disorder. In this condition, the outer layer of the brain (the cerebral...

    February 28, 2026 • Rx Neurology (A - Z)
  9. Cortical Dysgenesis with Pontocerebellar Hypoplasia Due to TUBB3 Mutation

    DefinitionCortical dysgenesis with pontocerebellar hypoplasia due to TUBB3 mutation”. It can also be grouped under “complex cortical dysplasia with other brain malformations 1 (CDCBM1)” and “TUBB3-related...

    February 28, 2026 • Rx Neurology (A - Z)
  10. Lissencephaly Type 2 Without Muscular or Eye Involvement

    DefinitionLissencephaly type 2 without muscular or eye involvement is a very rare brain development problem present from birth. Doctors also call it cobblestone lissencephaly without muscular...

    February 1, 2026 • Rx Neurology (A - Z)
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Acute Necrotizing Encephalopathy

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.